World Antiviral Congress 2021 Agenda

 

San Diego, 30 November 2021 - 2 December 2021

Schedule

Create your personal agenda –check the favourite icon

Nov 3014:00
Conference pass
Nov 3014:10
Conference pass

Monoclonal antibody cocktail to treat COVID-19 and RSV

Emerging Approaches to Antivirals
Nov 3014:25
Conference pass

DNA encoded monoclonal antibody treatment for infectious disease and beyond

Emerging Approaches to Antivirals
Nov 3014:40
Conference pass

High potency broadly neutralising antibodies for SARS-CoV-2 and emerging coronaviruses

Emerging Approaches to Antivirals
Nov 3014:55
Conference pass

Leronlimab – a platform mab CCR5 antagonist and its role in antiviral indications

Emerging Approaches to Antivirals
Nov 3015:10
Conference pass

Novel antiviral bispecific antibodies to address the emergence of variants of SARS-CoV-2

Emerging Approaches to Antivirals
Nov 3015:25
Conference pass

Targeted, high-potency plasma polyclonal antibodies for COVID-19 and Influenza

Emerging Approaches to Antivirals
Dr Eddie Sullivan, President, Chief Executive Officer And Co-Founder, Sab Biotherapeutics Inc
Nov 3016:40
Conference pass

A novel genetic approach to antiviral therapies

Emerging Approaches to Antivirals
Nov 3017:25
Conference pass

Immunotherapeutics in the treatment of chronic Hepatitis B

Emerging Approaches to Antivirals
Nov 3017:40
Conference pass

Host cell metabolism as a target for the development of broad-spectrum antivirals

Emerging Approaches to Antivirals

Create your personal agenda –check the favourite icon

Dec 108:20
Conference pass
Dec 109:00
Conference pass

Keynote Panel: Are oral antivirals the answer to eradicating the COVID-19 pandemic?

Keynotes
  • What are the benefits of using oral antivirals compared to other forms?
  • Which pills are currently in development and when can we expect to see them on the market?
  • Once these are developed how do you think the rollout will look and who will be given priority access?
  • How do oral antivirals fit into the overall strategy of combating the virus?
Additional panellists TBC
Dec 110:00
Conference pass

Keynote panel: Vital steps in pandemic preparedness

Keynotes
  • What steps can we take to ensure we are more prepared for the next pandemic?
  • How can we build a collective antiviral tool kit to ensure we are equipped for the next pandemic?
  • What are the advantages of using host cell-targeted therapies?
  • How can the use of broad-spectrum antivirals improve the response to a pandemic?
Dec 111:40
Conference pass

Customer case studies of rapid vaccine analysis for Coronavirus, Influenza, and more

COVID-19 & Respiratory Diseases
Dec 111:55
Conference pass

Discovery of oral, broad-spectrum SARS-CoV-2 main protease inhibitors: advancing to clinical development

COVID-19 & Respiratory Diseases
Dec 112:10
Conference pass

SLV213, a novel broadly effective oral treatment against SARS-CoV-2, other Coronaviruses, and emerging viral threats

COVID-19 & Respiratory Diseases
Dec 112:25
Conference pass

Mission Possible: designing rock-solid In-vitro testing protocols to conquer the antiviral drug development process

COVID-19 & Respiratory Diseases
Dec 112:40
Conference pass

Developing potent orally bioavailable lipid analogs of Remdesivir nucleoside

COVID-19 & Respiratory Diseases
Dec 112:55
Conference pass

Understanding the biology and mechanisms behind post-acute sequelae of COVID-19

COVID-19 & Respiratory Diseases
Dr Steven Deeks, Professor of Medicine, University of California San Francisco
Dec 114:40
Conference pass

Panel: Challenges and key learnings from clinical trial designs

COVID-19 & Respiratory Diseases
  • What have we learnt from the pandemic about clinical trial designs?
  • How do we set clear end points that are standardized and ensure studies are comparable and provide conclusive results?
  • Do we need to change the structure of clinical trial designs? And if so to what?
  • Is it ethical to use a placebo study in a pandemic?
Additional panellists TBC
Dr Barbara Rath, Chair of the ISIRV Epidemiology Group and Board Member with ISIRV and ESGREV and Co-founder & Chair, Vienna Vaccine Safety Initiative
Dr John Beigel, Associate Director, Clinical Research, National Institute of Health - NIAID
Dec 115:55
Conference pass

Accelerating the process from academic drug discovery to pharmaceutical industry support

COVID-19 & Respiratory Diseases
Dr George Painter, Professor of Pharmacology and Chemical Biology, Emory University
Dec 116:40
Conference pass

Short presentations: Antiviral administration delivery routes

COVID-19 & Respiratory Diseases
  1. An oral antiviral agent to inhibit replication of RNA viruses Dr Wendy Painter, CMO, Ridgeback Biotherapeutics
  2. Lung and respiratory tissue vaped delivery of antiviral drug regimens John Gregg, CEO & President, BalinBac
  3. Transdermal delivery of Influenza antivirals via a microneedle patch Dr Elke Lipka, Ph.D, MBA, CEO, TSRL, Inc.

Create your personal agenda –check the favourite icon

Dec 209:00
Conference pass

Developing a functional cure for Hepatitis B

HIV & Hepatitis
  • What is the current landscape for HBV treatment?
  • Are there any novel approaches for treatment being developed?
  • How close are we to discovering a cure for HBV?
  • What are the future strategies for managing HBV if a functional cure is developed?
  • How will a functional cure impact disease burden?
Dr Tom Evans, Chief Scientific Officer, Vaccitech
Dr Gaston Picchio, Chief Development Officer, Arbutus Biopharma Corporation
Dec 210:00
Conference pass

Panel: Achieving global access to HIV treatment

HIV & Hepatitis
  • How do we acknowledge and address health inequalities in providing global access to treatment?
  • How to address the prioritisation of access to treatment globally?
  • What methods are in place to help provide lifesaving treatment for HIV on a global scale?
  • What novel technology is available to enable treatment is available in remote locations?
Additional Panellists TBC
Dr Michael Wohlfeiler, Chief of Medicine, AIDS Healthcare Foundation
Paul Schaper, Executive Director of Global Pharmaceutical Public Policy, Merck
Dec 211:40
Conference pass

Panel: Streamlining the antiviral process-What can we learn from HIV

HIV & Hepatitis
  • What effect does 40 years’ worth of experience have on drug discovery vs little experience for an emerging disease?
  • How to effectively look at drug repurposing? How does using existing/ approved drugs affect timelines?
  • What complexities come with combining drug treatments and how can we overcome these in the future for emerging diseases?
  • How to effectively balance efficacy and toxicity?
Additional Panellists TBC
Dec 212:55
Conference pass

HBsAg Loss and Transaminase Flares: Therapeutic Implications for Functional Cure of HBV

HIV & Hepatitis
Dec 214:10
Conference pass

Title TBC: A long-acting injectable antiviral for the prevention and treatment of HIV

HIV & Hepatitis
Dr Matthew Bosse, VP and Global Medical Lead, ViiV Healthcare
Dec 214:40
Conference pass

A database to represent, store and analyse HIV drug resistance

HIV & Hepatitis
Dr Robert Shafer, Professor of Medicine-Infectious Diseases, Stanford University School of Medicine (USA)
Dec 215:10
Conference pass

Developing TLR7 agonists to treat diverse range of viral diseases including HBV, HCV and HIV

HIV & Hepatitis
last published: 27/Oct/21 14:45 GMT

For sponsorship opportunities

Thomas Hall
thomas.hall@terrapinn.com

For speaking opportunities

Ellie Whitehead
Ellie.Whitehead@terrapinn.com

Co-located with:

World Vaccine & Immunotherapy Congress West Coast